ProMIS' shareholders show overwhelming support for all resolutions, returning all six directors, and ratifying the Shareholder Rights Plan
TORONTO, July 5, 2016 /CNW/ - ProMIS Neurosciences ("ProMIS" or the "Company"), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced the voting results from the Company's annual meeting of shareholders held on June 30th in Toronto (the "Meeting").
The Company is pleased to announce that all of the resolutions announced in the Management Proxy Circular dated May 20, 2016 and placed before the Meeting were overwhelmingly approved by the shareholders. In particular:
1. The following directors were elected, with the following voting results for each nominee:
|
DIRECTOR
|
|
|
FOR
|
|
|
WITHHELD
|
|
Neil Cashman
|
|
|
43,753,734
|
|
|
40,200
|
|
Elliot Goldstein
|
|
|
43,758,734
|
|
|
34,500
|
|
Patrick D. Kirwin
|
|
|
43,758,734
|
|
|
34,500
|
|
Johannes Roth
|
|
|
42,511,734
|
|
|
1,281,500
|
|
Eugene Williams
|
|
|
43,758,734
|
|
|
34,500
|
|
William Wyman
|
|
|
42,821,734
|
|
|
971,500
|
2. PricewaterhouseCoopers, Chartered Accountants, were re-appointed auditor of the Corporation. Shares voted by proxy represented 47,965,510 votes for and 972,200 votes withheld.
3. The resolution of the disinterested shareholders to ratify, confirm and approve the repricing of certain stock options was passed. Shares voted by proxy represented 39,089,184 votes for and 1,534,050 against. In addition, there were 3,170,000 votes to Insiders, which were not counted in the tally of the votes cast on this resolution.
4. The resolution to ratify, confirm and approve the Shareholder Rights Plan was passed. Shares voted by proxy represented 43,434,734 votes for and 358,500 against.
Please refer to the Company's Management Proxy Circular available on SEDAR at www.sedar.com for more details on the matters discussed at the Meeting.
About ProMIS Neurosciences, Inc.
The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and ALS.
ProMIS Neurosciences' proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platforms—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has three preclinical monoclonal antibody therapeutics against this target.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
The information in this release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information please consult the Company's website at:
www.promisneurosciences.com
Follow us on Twitter
Like us on LinkedIn
SOURCE ProMIS Neurosciences Inc. 
For further information: NATIONAL Equicom: Michael Moore: mmoore@national.ca; Abby Garfunkel: agarfunkel@national.ca; or contact Dr. Elliot Goldstein, President and Chief Executive Officer, ProMIS Neurosciences Inc., Tel. 415 341-5783, Elliot.goldstein@promisneurosciences.com